v3.26.3
Segment Information and Geographic Data - Operating Segment Selected Financial Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:                
Revenue $ 285,970     $ 180,855     $ 743,836 $ 475,437
Costs and operating expenses:                
Cost of goods sold 27,759     20,257     72,127 56,728
Collaboration expenses 105,828     63,307     269,474 159,515
Direct research and development expenses by program:                
Research and development 32,786     24,166     101,160 62,244
Selling, general and administrative 65,361     49,104     190,378 139,497
Total operating expenses 231,734     156,834     633,139 417,984
Other income, net 4,821     3,136     12,186 8,146
Income before income taxes 59,057     27,157     122,883 65,599
Provision for income taxes (11,712)     (8,722)     (27,514) (20,793)
Net income 47,345 $ 25,432 $ 22,592 18,435 $ 17,832 $ 8,539 95,369 44,806
Other significant non-cash items:                
Share-based compensation expense 13,065     10,144     34,757 26,768
Non-cash lease expense 1,005     944     3,010 2,703
Deferred income taxes (6,565)     4,227     619 9,864
ARCALYST                
Direct research and development expenses by program:                
Research and development 176     269     849 795
KPL-387                
Direct research and development expenses by program:                
Research and development 17,250     11,380     54,844 25,043
KPL-1161                
Direct research and development expenses by program:                
Research and development 1,621     1,792     3,342 2,262
Abiprubart                
Direct research and development expenses by program:                
Research and development 77     708     306 5,710
Unallocated research and development expenses                
Direct research and development expenses by program:                
Research and development 13,662     10,017     41,819 28,434
Product revenue, net                
Revenue:                
Revenue 285,970     180,855     $ 743,836 $ 475,437
Pharmaceutical                
Revenue:                
Revenue $ 285,970     $ 180,855